Tonix Pharmaceuticals Holding Corp

+0.02 (+4.32%)
Products, Regulatory, Other Pre-Announcement

Tonix Pharmaceuticals Achieves 50 Percent Enrollment In Rally, The Second Phase 3 Study Of TNX-102 Sl For Management Of Fibromyalgia

Published: 03/15/2021 11:12 GMT
Tonix Pharmaceuticals Holding Corp (TNXP) - Tonix Pharmaceuticals Achieves 50 Percent Enrollment in Rally, the Second Phase 3 Study of Tnx-102 Sl for Management of Fibromyalgia.
Tonix Pharmaceuticals Holding Corp - Topline Results of Approximately 670 Participants in Rally Expected Q4 2021.
Tonix Pharmaceuticals - Enrollment Continues in Phase 3 Rally Study, With Interim Analysis of First 50 Percent of Participants Expected Q3 2021.
Tonix Pharmaceuticals - If Topline Results Are Positive, We Expect to Be in a Position to Submit NDA for Tnx-102 Sl for Fibromyalgia to FDA in 2022.